Google Ventures led a $135m Series B round in Chroma Medicine, with participation from ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. "In the year since launch, we have made significant progress in advancing the pioneering work of our scientific founders towards harnessing the power of the cell's epigenome to regulate gene expression and developing a robust portfolio of single-dose epigenetic editing therapeutics. We're grateful to this exceptional syndicate of investors, whose commitment enables our ongoing drive to introduce this new class of precision genomic medicines with curative potential to patients with serious illnesses," Catherine Stehman-Breen, Chroma CEO.